This DLBCL subtype is usually characterized by extranodal involvement, molecular findings associated with immune evasion, the presence of recurrent MYD88 L265P and CD79B mutations, and worse clinical outcomes [63]. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.